Vernalis plc (VER) Hits New 1-Year Low at $12.25
Shares of Vernalis plc (LON:VER) reached a new 52-week low during mid-day trading on Friday . The company traded as low as GBX 12.25 ($0.16) and last traded at GBX 13.25 ($0.18), with a volume of 162,834 shares changing hands. The stock had previously closed at GBX 14.12 ($0.19).
A number of brokerages have commented on VER. Panmure Gordon reiterated a “hold” rating and issued a GBX 31 ($0.41) price objective on shares of Vernalis plc in a research report on Monday, August 7th. Stifel Nicolaus reduced their price objective on Vernalis plc from GBX 24 ($0.32) to GBX 21 ($0.28) and set a “hold” rating for the company in a research report on Monday, August 7th. RX Securities reiterated a “buy” rating on shares of Vernalis plc in a research report on Monday, August 7th. Finally, N+1 Singer reiterated a “hold” rating and issued a GBX 28 ($0.37) price objective on shares of Vernalis plc in a research report on Monday, August 7th. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Vernalis plc presently has an average rating of “Hold” and an average price target of GBX 39.40 ($0.52).
The stock’s market capitalization is GBX 69.75 million. The company has a 50 day moving average price of GBX 15.56 and a 200 day moving average price of GBX 18.61.
Vernalis plc (LON:VER) last posted its earnings results on Tuesday, September 12th. The company reported GBX (4.10) (($0.05)) EPS for the quarter, beating the consensus estimate of GBX (4.50) (($0.06)) by GBX 0.40 ($0.01). Vernalis plc had a negative return on equity of 23.94% and a negative net margin of 69.02%. The company had revenue of GBX 2,079 million for the quarter. Analysts expect that Vernalis plc will post ($5.57) earnings per share for the current fiscal year.
Vernalis plc Company Profile
Vernalis plc is a commercial-stage pharmaceutical company. The Company is engaged in the research, development and commercialization of pharmaceutical products. The Company operates through two segments: Commercial, which covers all areas relating to the commercial sale of pharmaceutical products, the manufacture and distribution directly related to that activity, and Research and Development, which includes all activities related to the research and development of pharmaceutical products for a range of medical disorders.
Receive News & Ratings for Vernalis plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vernalis plc and related companies with MarketBeat.com's FREE daily email newsletter.